Novel GLP-1–glucagon receptor co-agonist looks good for treating MASH

15 giờ trước
Jairia Dela Cruz
Jairia Dela CruzSenior Medical Writer; MIMS
Jairia Dela Cruz
Jairia Dela Cruz Senior Medical Writer; MIMS
Novel GLP-1–glucagon receptor co-agonist looks good for treating MASH

In patients with metabolic dysfunction-associated steatohepatitis (MASH), once-weekly treatment with the GLP-1–glucagon receptor co-agonist efinopegdutide is associated with higher rates of MASH resolution without worsening of fibrosis compared with placebo, according to the phase IIb MK-6024 P013 study.

“All three doses of efinopegdutide showed superiority over placebo for the primary endpoint, MASH resolution without worsening of fibrosis at week 52,” reported lead investigator Prof Eric Lawitz from Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, US, and colleagues.

In the modified intention-to-treat analysis population, the proportions of participants meeting the primary endpoint were 56 percent with efinopegdutide 4 mg, 63 percent with 7 mg, and 61 percent with 10 mg vs 13 percent with placebo (p<0.0001 for all comparisons). [Lancet 2026;doi:10.1016/S0140-6736(26)02043-X]

For the key secondary endpoint, fibrosis regression (ie, one-stage improvement without worsening of steatohepatitis) occurred in 43 percent of participants in the efinopegdutide 4-mg group, 52 percent in the 7-mg group, and 34 percent in the 10-mg group vs 21 percent in the placebo group (p=0.0038, p<0.0001, and p=0.072, respectively).

The most common adverse events (AEs) with efinopegdutide were gastrointestinal, particularly vomiting, with the highest rates documented in the efinopegdutide 10-mg group. AEs leading to discontinuation of study intervention occurred more frequently in the efinopegdutide 10-mg group (11 percent) than in the 4- or 7-mg group (3 percent to 4 percent) or the placebo group (1 percent).

“In this study, efinopegdutide 7 mg showed the strongest overall balance of histological benefit and tolerability among the efinopegdutide doses and provided higher rates of MASH resolution without worsening fibrosis and fibrosis improvement of at least one stage without worsening of steatohepatitis than placebo,” Lawitz and colleagues noted.

The investigators highlighted the importance of the dual histological benefit—MASH resolution and fibrosis regression—achieved with efinopegdutide, “given the dynamic interplay between inflammation and fibrosis in chronic liver disease.”

“Moreover, both effects occurred largely independent of weight loss with numerically greater responses relative to semaglutide despite lower weight loss, suggesting therapeutic benefits beyond weight reduction,” they added.

MK-6024 P013 was conducted at 176 academic and community centres across 26 countries. The trial included 381 adults (mean age 53 years, 51 percent female) with biopsy-confirmed MASH and stage 2 or stage 3 fibrosis—a population that is generally representative of adults with MASH, as Lawitz and colleagues pointed out.

Baseline characteristics were similar across groups. Overall, 63 percent of participants had F2 fibrosis and 37 percent had F3 fibrosis. The mean age of participants was 53 years.

In the semaglutide group, MASH resolution occurred in 53 percent of participants, and fibrosis regression occurred in 25 percent.

“MK-6024 P013 offers the opportunity to improve and expand the therapeutic landscape of MASH, particularly for precision targeting, [with] dual GLP-1–glucagon receptor agonists having heterogeneous structural and potency ratios—roughly ranging from GLP-1 receptor-biased profiles in survodutide (around 8:1) and cotadutide (around 5:1), to efinopegdutide (around 2:1), to the equipotent engagement of pemvidutide (1:1)—to proven liver endpoints,” wrote Drs Silvia Sookoian and Carlos José Pirola, both from Maimónides University, Buenos Aires, Argentina, in an accompanying editorial. [Lancet 2026;doi:10.1016/S0140-6736(26)02193-8]  

“Future clinical trials should prioritize rigorous, double-blind, randomized, head-to-head comparisons at equipotent doses to clarify the true incremental benefit of glucagon receptor engagement, while carefully managing dropout bias to ensure histological endpoints are not confounded by tolerability-driven attrition,” Sookoian and Pirola added.